Operational Costs Compared: SG&A Analysis of Alkermes plc and Dynavax Technologies Corporation

A Decade of SG&A: Alkermes vs. Dynavax

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Alkermes plc and Dynavax Technologies Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes saw a staggering 245% increase in SG&A costs, peaking in 2023. This reflects their aggressive expansion and market penetration strategies. In contrast, Dynavax, while starting with significantly lower expenses, experienced an impressive 760% surge, indicating their rapid growth and scaling efforts.

Key Insights

• Alkermes: Consistent growth with a focus on steady market expansion.
• Dynavax: Rapid escalation in expenses, highlighting dynamic growth phases.

This analysis underscores the diverse strategies employed by these companies in navigating the competitive pharmaceutical sector. As they continue to evolve, understanding these financial dynamics offers valuable insights into their operational priorities.